Carriers of the NOS2(Lambaréné) polymorphism were significantly less likely to experience malarial attacks over 4 years compared to wild-type carriers (P=.002).
Cohort (n=200)
Does the NOS2(Lambaréné) polymorphism reduce malarial attacks in children?
The NOS2(Lambaréné) polymorphism is associated with increased baseline nitric oxide production and provides significant protection against malarial attacks in children.
p-value: p=.002
A point mutation in the promoter of the nitric oxide synthase 2 gene (NOS2), termed NOS2(Lambaréné) (NOS2-G954C), protects heterozygous carriers against severe malaria as effectively as the sickle cell trait. In a prospective longitudinal study, 841 individual infections of initially 200 children (151 wild-type vs. 49 NOS2(Lambaréné) carriers) were monitored for 4 years, to assess the rates of malarial attacks in the 2 groups; carriers of the NOS2(Lambaréné) polymorphism were significantly less likely to experience malarial attacks than were others (P=.002). The distribution of the NOS2(Lambaréné) polymorphism was investigated in malaria-endemic areas. It was found to be present with the highest frequency in Africa and at a lower frequency in Asia. Ex vivo studies showed that cells isolated from people with this polymorphism have a 7-fold higher baseline NOS activity, compared with the levels detected in cells from subjects with the wild-type gene (P=.003).
Kun et al. (2001) conducted a cohort in Malaria (n=200). NOS2(Lambaréné) (NOS2-G954C) polymorphism vs. Wild-type gene was evaluated on Malarial attacks (p=.002). Carriers of the NOS2(Lambaréné) polymorphism were significantly less likely to experience malarial attacks over 4 years compared to wild-type carriers (P=.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: